Today: 7 February 2026
Subscribe
Browse Category

Pharmaceuticals News 21 December 2025 - 23 December 2025

Eli Lilly Stock (LLY) After Hours Drops on Wegovy Pill Approval: What to Know Before the Market Opens Dec. 23, 2025

Eli Lilly Stock (LLY) After Hours Drops on Wegovy Pill Approval: What to Know Before the Market Opens Dec. 23, 2025

Eli Lilly and Company (NYSE: LLY) ended Monday’s regular session higher — then slipped after the closing bell as investors digested a major late-day headline from its biggest obesity rival, Novo Nordisk. LLY closed at $1,076.48 (+0.47%) at 4:00 p.m. ET on Monday, Dec. 22, 2025, then traded down about 1% in after-hours action, around $1,065.50 as of 6:18 p.m. ET. StockAnalysis+1 That after-hours dip matters because the news that hit late Monday is exactly the kind of development that can reprice sentiment around the hottest corner of big pharma: GLP‑1 weight-loss drugs — and, increasingly, GLP‑1 pills. LLY stock
23 December 2025
·····
AbbVie Stock News Today (Dec. 22, 2025): ABBV Holds Near $227 as Drug-Pricing Talks, Dividend Growth, and 2026 Catalysts Come Into Focus

AbbVie Stock News Today (Dec. 22, 2025): ABBV Holds Near $227 as Drug-Pricing Talks, Dividend Growth, and 2026 Catalysts Come Into Focus

AbbVie Inc. (NYSE: ABBV) is trading near recent highs on Monday, December 22, 2025, as investors weigh a powerful mix of policy risk, shareholder returns, and pipeline momentum heading into 2026. The big near-term variable isn’t a clinical readout—it’s Washington. After the White House unveiled sweeping “most-favored-nation” (MFN) drug-pricing agreements with nine large manufacturers on December 19, AbbVie remains one of the last major drugmakers still outside the deal. The White House+1 At the same time, AbbVie’s core fundamentals continue to be anchored by its immunology franchise—Skyrizi and Rinvoq—alongside a rising dividend profile and a pipeline that includes late-stage programs
22 December 2025
·····
Amgen Stock (AMGN) News Today: Trump Drug‑Price Deals, Analyst Forecasts, and What to Watch Next — Dec. 22, 2025

Amgen Stock (AMGN) News Today: Trump Drug‑Price Deals, Analyst Forecasts, and What to Watch Next — Dec. 22, 2025

Amgen Inc. (NASDAQ: AMGN) is back in the spotlight on Monday, December 22, 2025, as investors weigh a wave of White House drug‑pricing agreements, a fast‑moving “most‑favored‑nation” (MFN) pricing push, and what it could all mean for Amgen’s earnings power in 2026. The stock traded higher in Monday’s session, with market data showing shares around $331. While the headlines are centered on drug prices, the market’s reaction has been notably measured: several analyst notes published today suggest these deals may be designed to reduce political and tariff uncertainty more than they materially compress pharma profits—at least in the near term.
22 December 2025
·····
Alnylam Pharmaceuticals (ALNY) Stock on Dec. 22, 2025: Nasdaq-100 Debut, AMVUTTRA Momentum, Analyst Price Targets and the 2026 Outlook

Alnylam Pharmaceuticals (ALNY) Stock on Dec. 22, 2025: Nasdaq-100 Debut, AMVUTTRA Momentum, Analyst Price Targets and the 2026 Outlook

Dec. 22, 2025 — Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) is stepping into a new tier of market visibility today as its Nasdaq-100 Index membership takes effect ahead of the opening bell—an index catalyst that can influence near-term trading and broaden long-term institutional ownership. Nasdaq+1 ALNY was trading around $405.60 on Dec. 22 (time-stamped 16:37 UTC), up about 1.3% versus the prior close—an incremental move that nonetheless lands in the middle of a busier-than-usual news cycle for the RNAi leader. Below is a comprehensive roundup of the current news, forecasts, and market analysis circulating through Dec. 22, 2025, and what investors
22 December 2025
·····
Pfizer Stock Outlook for 2026: Oncology Momentum, Obesity Deals, and the Patent Cliff Investors Can’t Ignore

Pfizer Stock Outlook for 2026: Oncology Momentum, Obesity Deals, and the Patent Cliff Investors Can’t Ignore

As of Monday, December 22, 2025, Pfizer (NYSE: PFE) is once again at the center of a familiar market debate: is this a battered pharma giant destined to stay “dead money,” or a dividend-rich turnaround story that could surprise investors as its pipeline matures? The short-term reality is tough to miss. Pfizer has guided to flat-to-down revenue in 2026, with continued COVID-franchise erosion and an accelerating loss-of-exclusivity cycle. But the longer-term case—outlined in a wave of investor and analyst commentary this month—rests on whether Pfizer can execute in the two areas that matter most to its post-patent-cliff future: oncology and
22 December 2025
·····
AbbVie Stock (ABBV) Before the Market Opens on Dec. 22, 2025: Drug-Pricing Talks, Dividend Signals, and the Next Catalysts

AbbVie Stock (ABBV) Before the Market Opens on Dec. 22, 2025: Drug-Pricing Talks, Dividend Signals, and the Next Catalysts

AbbVie Inc. (NYSE: ABBV) heads into the Monday, December 22, 2025 U.S. market open with a familiar bull case—Skyrizi and Rinvoq continuing to replace lost Humira revenue—and a less familiar overhang: Washington’s accelerating push to reframe U.S. drug pricing through “most‑favored‑nation” style commitments and new direct-to-consumer programs. Below is what investors and traders should keep on their radar before the opening bell, using the most recent available company updates, analyst forecasts, and late‑breaking policy developments. 1) Where AbbVie stock stands heading into Monday AbbVie last closed at $226.82 (Friday, Dec. 19), up about 1.8% on the day. StockAnalysis+1 One detail
22 December 2025
·····
Eli Lilly (LLY) Stock: What to Know Before the U.S. Market Opens on Dec. 22, 2025

Eli Lilly (LLY) Stock: What to Know Before the U.S. Market Opens on Dec. 22, 2025

Eli Lilly and Company (NYSE: LLY) enters the final full holiday trading week of 2025 with momentum—and with headlines that can move the stock quickly in thin year‑end liquidity. The most important story remains Lilly’s dominance in obesity and diabetes medicines (Zepbound/Mounjaro), but investors are now pricing in what comes next: oral GLP‑1 candidates (orforglipron), next‑generation “triple agonist” retatrutide, and a shifting U.S. policy backdrop that’s pushing drugmakers toward direct-to-consumer pricing and discount channels. LLY last closed at $1,071.44 (Friday, Dec. 19) after a strong recent stretch that’s kept the stock near its highs. StockInvest Below is a pre‑market briefing—what
22 December 2025
·····
AbbVie Stock Week Ahead (Dec. 22–26, 2025): ABBV Holds Near $227 as Drug-Pricing Headlines Collide With Fresh Analyst Upgrades

AbbVie Stock Week Ahead (Dec. 22–26, 2025): ABBV Holds Near $227 as Drug-Pricing Headlines Collide With Fresh Analyst Upgrades

As of Sunday, December 21, 2025, AbbVie Inc. (NYSE: ABBV) heads into a holiday-shortened trading week with shares hovering near the mid-$220s, after a high-volume rebound into Friday’s close. The setup for the week ahead is defined by two competing forces: strong underlying fundamentals (Skyrizi/Rinvoq momentum, updated 2025 outlook, and a higher dividend) and a renewed policy overhang as Washington accelerates its latest push to align U.S. drug prices with lower international benchmarks. Below is a practical, week-ahead roadmap of the latest news, forecasts, and market analysis investors are weighing right now. ABBV stock snapshot entering the week AbbVie shares
21 December 2025
·····
Johnson & Johnson (JNJ) Stock Week Ahead: Drug-Pricing Politics, Talc Verdicts, and Fresh FDA Wins Set the Tone (Dec 22–26, 2025)

Johnson & Johnson (JNJ) Stock Week Ahead: Drug-Pricing Politics, Talc Verdicts, and Fresh FDA Wins Set the Tone (Dec 22–26, 2025)

As the market heads into a Christmas-shortened trading week, Johnson & Johnson (NYSE: JNJ) is entering the final stretch of 2025 with an unusually headline-heavy mix of catalysts: U.S. drug-pricing negotiations tied to the White House, new talc-related jury verdicts, and a string of FDA and clinical updates that reinforce the company’s longer-term growth narrative. As of the latest close (Friday, December 19, 2025), JNJ ended around $206/share, keeping the stock in a tight, late-year range while investors weigh whether policy risk and litigation uncertainty outweigh the steadier benefits of new product momentum and “defensive” healthcare positioning. MarketBeat Below is
21 December 2025
····
Eli Lilly Stock Week Ahead (Dec. 22–26, 2025): LLY Enters Holiday Week With Obesity-Drug Catalysts, Pricing Headlines, and Policy Risk

Eli Lilly Stock Week Ahead (Dec. 22–26, 2025): LLY Enters Holiday Week With Obesity-Drug Catalysts, Pricing Headlines, and Policy Risk

As of Sunday, December 21, 2025, Eli Lilly and Company (NYSE: LLY) heads into a holiday-shortened trading week near recent highs, after a busy stretch of headlines spanning next-generation obesity drugs, potentially accelerated FDA review timelines, price cuts aimed at widening access, and a fast-evolving U.S. drug-pricing agenda. The stock’s setup for the week ahead is straightforward: fundamentals and pipeline momentum remain the core bull case, while the key overhangs are pricing pressure, policy uncertainty, and headline-driven volatility typical of a late-December tape. Eli Lilly stock price check: where LLY stands heading into the week LLY last traded around $1,071
21 December 2025
···
Recursion Pharmaceuticals RXRX Stock News and Forecasts on December 21 2025

Recursion Pharmaceuticals RXRX Stock News and Forecasts on December 21 2025

Recursion Pharmaceuticals, Inc. stock (NASDAQ: RXRX) heads into the week of December 21, 2025 with investors focused on one thing above all: whether newly released clinical data can turn Recursion’s long-running “AI drug discovery” promise into a credible, repeatable pipeline story that ultimately becomes commercial revenue. The near-term backdrop is noisy. RXRX has been highly volatile for years, and even now the share price sits far below its prior highs, a reality that shapes how every catalyst is interpreted. The Motley Fool Below is a roundup of the key RXRX stock news, fresh filings, analyst forecasts, and the most cited
21 December 2025
·····
Pfizer Stock (PFE) News Today: 2026 Guidance, Analyst Forecasts, Dividend Outlook, and Pipeline Catalysts (Updated Dec. 21, 2025)

Pfizer Stock (PFE) News Today: 2026 Guidance, Analyst Forecasts, Dividend Outlook, and Pipeline Catalysts (Updated Dec. 21, 2025)

Pfizer Inc. (NYSE: PFE) is heading into 2026 with a familiar mix of strengths and stress fractures: a fortress-scale commercial footprint and one of Big Pharma’s deepest development machines—paired with fading COVID-era revenue, looming loss-of-exclusivity headwinds, and heightened political pressure on U.S. drug pricing. As of the most recent close (Friday, Dec. 19), Pfizer stock finished around $25.19, leaving shares squarely in the “mid‑$20s” range where they’ve been pinned for much of the post-pandemic reset. MarketBeat+1 What changed in December—and why investors are still arguing about Pfizer stock—comes down to three big storylines: Below is a comprehensive, up-to-date roundup of
21 December 2025
·····
1 … 32 33 34 35 36 … 56

Stock Market Today

Sembcorp Industries share price: what to watch after Friday dip as Feb 25 results near

Sembcorp Industries share price: what to watch after Friday dip as Feb 25 results near

7 February 2026
Singapore, Feb 7, 2026, 15:23 SGT — The market has closed. Sembcorp Industries Ltd (SGX: U96) slipped 0.33% to finish Friday at S$6.05, with the stock moving in a narrow S$6.00-S$6.05 band. Volume landed at roughly 4.3 million shares. (Investing.com) Heading into Monday, the stock faces two key catalysts that could quickly shift sentiment: upcoming full-year results later this month, plus updates on the company’s planned Australia expansion through Alinta Energy. The decline on Friday coincided with a downturn across Singapore stocks. According to The Business Times, the Straits Times Index gave up 0.8%, ending a streak of three straight
Hongkong Land share price drops 4% despite fresh buyback — what investors watch next

Hongkong Land share price drops 4% despite fresh buyback — what investors watch next

7 February 2026
Hongkong Land shares fell 4.2% to US$8.18 in Singapore on Friday after the company disclosed a buyback of 170,000 shares at US$8.5252 each on Feb. 5, with plans to cancel them. The drop followed a volatile week marked by a new Singapore real estate fund launch and an expanded buyback programme. Investors are watching for the group’s annual results on March 5.
Go toTop